MD Anderson Cancer Center researchers used both clinical samples and laboratory models to demonstrate that higher levels of a specific mucin-degrading bacteria are associated with a higher incidence of febrile neutropenia and that treatment with antibiotics helped restore those levels to normal.
CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has entered into a collaborative partnership with Einstein Hospital Israelita in Sao Paulo, Brazil, aimed at accelerating the adoption of cell therapy in Brazil and all of Latin America.
